OncoMatch/Clinical Trials/NCT04848064
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Is NCT04848064 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Mogamulizumab and Natural Killer Cell Therapy for recurrent adult t-cell leukemia/lymphoma.
Treatment: Cyclophosphamide · Fludarabine · Mogamulizumab · Natural Killer Cell Therapy — This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IB, IIA, IIB, III, IIIA, IIIB, IV, IVA, IVB
stage IB-IVB relapsed or refractory cutaneous T-cell lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
relapsed or refractory cutaneous T-cell lymphoma after 1 prior line of systemic therapy
Must have received: chemotherapy
Patients with adult T-cell leukemia/lymphoma (ATLL)...must have had at least one standard chemotherapy
Cannot have received: mogamulizumab
Exception: unless stopped previously for reasons other than progression or toxicity
Prior therapy with mogamulizumab unless stopped previously for reasons other than progression or toxicity.
Cannot have received: investigational therapy
Investigational therapies in the 2 weeks prior to beginning treatment on trial
Lab requirements
Blood counts
Absolute neutrophil count >= 1000/mm^3; Platelet count >= 50,000/mm^3
Kidney function
Calculated creatinine clearance >= 50 ml/min (by the Crockroft-Gault equation)
Liver function
Total bilirubin <= 2 x ULN; AST (SGOT) and ALT (SGPT) <= 3 x ULN (<= 5 x ULN with hepatic involvement by lymphoma)
Absolute neutrophil count >= 1000/mm^3; Platelet count >= 50,000/mm^3; Total bilirubin <= 2 x upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) <= 3 x ULN (<= 5 x ULN with hepatic involvement by lymphoma); Calculated creatinine clearance >= 50 ml/min (by the Crockroft-Gault equation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04848064 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mogamulizumab, investigational therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IB or IIA or IIB or III or IIIA or IIIB or IV or IVA or IVB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify